Physiomics wins new contract with Numab Therapeutics.

AIM-listed biotech Physiomics has announced a new contract with client Numab Therapeutics to help development activities for the latter's oncology pipeline.

Physiomics
14 April 2026 15:58:15

Source: Sharecast

The contract, which is set to begin this month and last sometime in the third quarter, will see Physiomics develop a so-called mechanistic pharmacokinetic-pharmacodynamic modelling framework to support Numab in its proof-of-concept work for a new programme.

Physiomics will interpret data, optimise experimental design and development strategy, and inform key go/no-go decision-making for Numab, it said.

"We are thrilled to extend our collaboration with Numab Therapeutics to provide insights that can support robust proof-of-concept decision-making for this early oncology programme," said Physiomics chief executive Peter Sargent.

The stock was up 1.8% at 0.51p by 1456 BST.

See the latest RNS on Investegate.

No financial details regarding the contract were published.

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.